Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand

Cancer Research

Volumn 61, Issue 15, 2001, Pages 5833-5842

  Naumann, Ulrike ^a   Wick, Wolfgang ^a   Weller, Michael ^a   Kügler, Sebastian ^a   Bähr, Mathias ^a   Schulz, Jorg B ^a   Wolburg, Hartwig ^a   Rascher, Gesa ^a   Conseiller, Emmanuel ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FAS LIGAND; MUTANT PROTEIN; PROTEIN P53;

ADENOVIRUS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL VIABILITY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; GENE TRANSFER; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR SUPPRESSOR GENE;

ADENOVIRUSES, HUMAN; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; CASPASES; CELL DIVISION; CELL SURVIVAL; COMBINED MODALITY THERAPY; CYTOCHROME C GROUP; FAS LIGAND PROTEIN; GENE THERAPY; GENES, P53; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; MUTATION; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035422775     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
2. A Phase I/II study of herpes simplex virus type I thymidine kinase "suicide" gene therapy for recurrent glioblastoma
3. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme
4. Chronic brain inflammation and persistent herpes simplex virus I thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
5. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats
6. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma
7. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis
8. Characterization of p53 and p21 functional interaction in glioma cells en route to apoptosis
9. Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status
10. Combined radiation and p53 gene therapy of malignant glioma cells
11. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
12. CTS 1: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties
13. Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors expressing MDM2
14. Loco-regional Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo
15. Culturing hippocampal neurons and astrocytes from fetal rodent brain
16. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses
17. Transduction of axotomized retinal ganglion cells by adenoviral vector administration at the optic nerve stump: An in vivo model system for the inhibition of neuronal cell death
18. WAF/CIPI protein accumulation
19. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release
20. Death ligand/receptor-independent caspase activation mediates drug-induced cell death in malignant glioma cells
21. Effect of more than one inhibitors
22. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines
23. Glioma cell sensitivity to topotecan: The role of p53 and topotecan-induced DNA damage
24. Structural elements common to mitosis and apoptosis
25. Functions of the mdm2 oncogene
26. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
27. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis
28. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing
29. PERP, an apoptosis-associated target of p53, is a novel member of PMP-22/gas3 family
30. A model for p53-induced apoptosis
31. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis
32. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
33. p53 and brain tumors: From gene mutations to gene therapy
34. Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity
35. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transaction
36. CD95 ligand: Lethal weapon for malignant glioma?
37. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
38. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
39. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines